source
- BMS abandons $100 million Orum degrader-antibody conjugate after early phase-1 resultsBristol Myers Squibb has decided to stop development of the degrader‑antibody conjugate it purchased from Orum Therapeutics for $100 million after reviewing data from a phase‑1 trial. The experime…
- Electra Therapeutics raises $350 million in oversubscribed IPOElectra Therapeutics, a South San Francisco biotech focused on inflammation, completed its Nasdaq IPO, selling 23.3 million shares at $15 each and generating $350 million in gross proceeds. This a…